The first wave of PARP inhibitors has improved outcomes in people with a variety of solid tumors. However, Idience has identified opportunities to improve the efficacy of existing drugs and ...
Hosted on MSN11mon
Saruparib demonstrates early efficacy in breast cancers with DNA repair defects in Phase I/II trialPoly-ADP ribose polymerase (PARP) inhibition previously was shown ... The most common adverse events were anemia, neutropenia, thrombocytopenia, fatigue and asthenia. According to Yap, the safety ...
Maintenance with niraparib and bevacizumab can be effective in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor.
Results from the PAOLA-1 study showed that the PARP inhibitor drug significantly increased the time women lived without disease progression when added to the standard-of-care, Genentech’s ...
Scientists at St. John’s University, The University of Pennsylvania and Université de Montréal have identified poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the ...
AbbVie’s hopes of getting a so-called PARP inhibitor cancer drug to market are fading after its veliparib failed in two late-stage studies. AstraZeneca’s Lynparza (olaparib) is becoming well ...
LAE120 is a novel, allosteric and highly potent USP1 inhibitor, displaying monotherapy potency and combination activity with PARP inhibitor in HRD (homologous recombination deficiency) cancers.
Pharmaceutical Technology on MSN3mon
Eisbach Bio positions HRD-targeting therapy to supplant PARP inhibitorsA $4.75m grant will support the development of EIS-12656, which is being studied alone and in combination with PARP inhibitors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback